Perirenal fat diameter measured by echography could be an early predictor of lipodystrophy in HIV type 1-infectecl patients receiving highly active antiretroviral therapy

22Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Echographically measured thicknesses of perirenal and subcutaneous fat, as well as serum metabolic and anthropometric parameters, were evaluated in 74 human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy (HAART), 22 of whom were HAART-naive at baseline, who were followed-up for 27 months to detect predictive factors of lipodystrophy. Perirenal fat diameter (PRFD) at baseline differed in HAART-naive and HAART-experienced patients (P 2.6 mm at baseline or >4.9 mm during receipt of HAART suggested lipodystrophy predisposition. PRFD correlated significantly with other metabolic and anthropometric parameters. Echographically measured PRFD is associated with lipodystrophy and could be used as an early predictor of this syndrome in treatment-naive patients starting HAART.

Cite

CITATION STYLE

APA

Asensi, V., Martíin-Roces, E., Carton, J. A., Collazos, J., Maradona, J. A., Alonso, A., … Arribas, J. M. (2004). Perirenal fat diameter measured by echography could be an early predictor of lipodystrophy in HIV type 1-infectecl patients receiving highly active antiretroviral therapy. Clinical Infectious Diseases, 39(2), 240–247. https://doi.org/10.1086/421774

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free